Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/49734
Título: Pioglitazone: Beyond glucose control
Autores/as: De Pablos-Velasco, Pedro 
Clasificación UNESCO: 32 Ciencias médicas
3205 Medicina interna
Palabras clave: Type-2 Diabetes-Mellitus
Congestive-Heart-Failure
Adverse Cardiovascular Events
Intima-Media Thickness
High-Risk Patients, et al.
Fecha de publicación: 2010
Publicación seriada: Expert Review of Cardiovascular Therapy 
Resumen: Pioglitazone is an oral antidiabetic agent that decreases insulin resistance in adipose tissue, liver and muscles. This action is mediated by its link to a nuclear receptor called peroxisome proliferator-activated receptor-gamma. By improving insulin sensitivity, hepatic glucose production decreases and glucose uptake increases in the peripheral tissues. Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin and C-reactive protein levels. These make pioglitazone treatment effective beyond glucose control. In this article, current evidence concerning pioglitazone in the treatment of Type 2 diabetes will be reviewed.
URI: http://hdl.handle.net/10553/49734
ISSN: 1477-9072
DOI: 10.1586/ERC.10.98
Fuente: Expert Review of Cardiovascular Therapy[ISSN 1477-9072],v. 8, p. 1057-1067
Colección:Artículos
Vista completa

Citas SCOPUSTM   

13
actualizado el 24-mar-2024

Citas de WEB OF SCIENCETM
Citations

10
actualizado el 25-feb-2024

Visitas

36
actualizado el 23-mar-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.